Latest News

Latest News

Who Notices When a Clinical Model Drifts?

Who Notices When a Clinical Model Drifts?

Most clinical prediction tools get one big exam. Someone pulls a retrospective cohort, runs the numbers, shows a committee a curve, and the tool goes live. After that the exam rarely gets repeated, so model drift can go unnoticed. The emergency department keeps...

read more
UK Lab Space in 2026: Record Vacancy, Regional Squeeze

UK Lab Space in 2026: Record Vacancy, Regional Squeeze

UK lab space demand reached a record in 2026. So did UK lab space vacancy. CoStar data shows national laboratory vacancy hit a record 14.3% in the second quarter of 2026. That is more than double the level of two years earlier. Yet some regional science parks say...

read more
When the AI Inside a Medical Device Belongs to Someone Else

When the AI Inside a Medical Device Belongs to Someone Else

Medical device manufacturers have long relied on third-party technology. Generative AI, however, presents new challenges for manufacturers of AI medical devices, who may have little influence over how the external model is developed. The technology may be outside of...

read more

Join The Future Of Life Sciences Media

 

In a world overflowing with information, LifeScienceDaily.news stands apart as the dedicated space where life sciences professionals share what’s new, what’s next, and why it matters, all in real time.

 

 

Don’t wait for the media to pick up your story. Be the media.

More News

Kidney Care’s $2.5 Billion Timing Problem

Kidney Care’s $2.5 Billion Timing Problem

Capital is flowing to the wrong point on the disease timeline Kidney care has attracted more than $2.5 billion in investment capital over the past five years. The amount tells a clear story. Unfortunately, it may be the wrong one. Investment has mostly concentrated on...

read more
Beyond Weight Loss: What Emerging GLP-1 Research Reveals

Beyond Weight Loss: What Emerging GLP-1 Research Reveals

For many years, the perception of obesity and metabolic syndrome has largely been framed within the context of lifestyle and individual choices. However, an unprecedented paradigm shift is taking place as researchers gain a more profound insight into the physiological...

read more
GLP-1 Side Effects: What the Evidence Actually Says

GLP-1 Side Effects: What the Evidence Actually Says

An estimated 1.6 million adults in Great Britain used a GLP-1 or dual GLP-1/GIP medicine for weight loss in the year to early 2025. The MHRA has strengthened UK product information for these medicines twice since January 2026. Despite that scale of use, the evidence...

read more
Kidney Care’s $2.5 Billion Timing Problem

Kidney Care’s $2.5 Billion Timing Problem

Capital is flowing to the wrong point on the disease timeline Kidney care has attracted more than $2.5 billion in investment capital over the past five years. The amount tells a clear story. Unfortunately, it may be the wrong one. Investment has mostly concentrated on...

read more
Beyond Weight Loss: What Emerging GLP-1 Research Reveals

Beyond Weight Loss: What Emerging GLP-1 Research Reveals

For many years, the perception of obesity and metabolic syndrome has largely been framed within the context of lifestyle and individual choices. However, an unprecedented paradigm shift is taking place as researchers gain a more profound insight into the physiological...

read more
GLP-1 Side Effects: What the Evidence Actually Says

GLP-1 Side Effects: What the Evidence Actually Says

An estimated 1.6 million adults in Great Britain used a GLP-1 or dual GLP-1/GIP medicine for weight loss in the year to early 2025. The MHRA has strengthened UK product information for these medicines twice since January 2026. Despite that scale of use, the evidence...

read more

Featured Articles

DNA double helix beside a microscope, test tubes and a pipette over a petri dish, representing life science publishing

Life Science Publishing: Our First Year, and Where You Fit In

Almost a year ago, Life Science Daily News published its first articles with a simple belief. Specialist science deserves a specialist stage. Since then, that belief has grown into a global readership and an active community of contributors. This is the story of our...
FDA building exterior alongside pharmaceutical laboratory setting representing drug approval decisions

FDA Drug Approval Decisions

Last updated 28 October 2026. Covering target action dates from October 2026 to February 2027. October changed how this tracker has to be read. Six FDA drug approval decisions landed in the month, and four arrived ahead of target. One cleared roughly 12 weeks early,...
gloved hands holding a glowing blue sample vial (labelled LOT: 24-B1, SAMPLE: GENO-) with a lab researcher working in the background.

CRISPR Gene Editing 2026: Rare Diseases, Cancer and Autoimmune

CRISPR gene editing in 2026 is no longer a technology to watch. It is a technology delivering results. Across three distinct disease areas, rare inherited conditions, haematologic and solid cancers, and autoimmune disease, clinical programmes are accumulating...
Three GLP-1 drug pipeline injection pens and oral tablets beside a clinical trial efficacy chart on a clipboard

The GLP-1 Drug Pipeline: Every Candidate to Watch in 2026

The GLP-1 drug pipeline has become one of the most consequential and closely watched in modern pharmaceutical history. In 2026, the class of glucagon-like peptide-1 receptor agonists is no longer defined solely by Ozempic and Wegovy. A new generation of oral tablets,...
Sjögren's disease diagnosis: close-up of a dry, irritated eye with eye drops being applied

Anti-Ro52 vs Anti-Ro60: Advancing Sjögren’s Disease Diagnosis

Autoantibody testing is a central part of autoimmune disease diagnosis, including Sjögren’s disease (SjD). The American College of Rheumatology and European Alliance of Associations of Rheumatology (ACR/EULAR) classification criteria for SjD incorporate ocular and...

Further News

Weekly News Roundup | 10 August 2026

Weekly News Roundup | 10 August 2026

Life science news 10 August 2026: Curium pays up to $8 billion for Lantheus to build a radiopharma giant, AstraZeneca’s shares slide on reported $400 billion Bristol Myers Squibb talks, and the MHRA approves a first-in-class BTK inhibitor for chronic hives in an...

read more
Clinical Trials Roundup | 07 Aug 2026

Clinical Trials Roundup | 07 Aug 2026

Merck’s tulisokibart meets its primary and key secondary endpoints in a Phase 2 hidradenitis suppurativa study but misses in systemic sclerosis-associated interstitial lung disease, Eli Lilly’s olomorasib receives a second FDA Breakthrough Therapy designation in KRAS...

read more
Why AI Pilots Fail in Life Sciences

Why AI Pilots Fail in Life Sciences

Misaligned incentives, the wrong unit of work, and a probabilistic model where the process demands a reproducible one A draft annex to European GMP guidance, out for consultation until October 2025, contains the bluntest sentence yet written about AI in regulated...

read more
New Approach Methodologies: What Regulators Now Accept

New Approach Methodologies: What Regulators Now Accept

New approach methodologies have moved from the margins of preclinical science to the centre of regulatory policy. Since publishing its Roadmap to Reducing Animal Testing in Preclinical Safety Studies in April 2025, the United States Food and Drug Administration has...

read more
Evaluating Retrieval Systems for Clinical AI

Evaluating Retrieval Systems for Clinical AI

Clinical decision support is not new, and it does not have to be complex to work. If anything, the simpler it is, the more likely clinicians are to use it. The best-known earlier example is the WHO surgical safety checklist, developed by a team led by Atul Gawande,...

read more
CSRD Reporting: What Has Changed for European Biotech

CSRD Reporting: What Has Changed for European Biotech

The European Union has rewritten its sustainability disclosure rules. The consequences for the life sciences sector are substantial. CSRD reporting was once expected to capture tens of thousands of companies across the bloc. It now applies to a far smaller group of...

read more

Further News

Small Cell Lung Cancer Treatment Filing Pulled Ahead of FDA Decision

Daiichi Sankyo and Merck have withdrawn a United States application for ifinatamab deruxtecan. The move takes a prospective small cell lung cancer treatment out of the American regulatory queue. The companies announced the withdrawal by Business Wire at 4:30pm Eastern...

Overcoming the Delivery Barrier: Systemic Virotherapy and Metastatic Cancer

The oncology field has made remarkable progress over the past two decades in defining the molecular and immunological drivers of cancer. Modern targeted approaches and immunotherapies have transformed outcomes for many patients, particularly when treating primary or...

Why Digital Therapeutics Struggle to Enter Clinical Workflows

The practical barriers between promising digital therapeutic research and routine care, from validation and safety reporting to staff adoption and patient experience. A digital therapeutic can produce encouraging research results, receive regulatory clearance and...

Weekly News Roundup | 28 September 2026

Life science news 28 September 2026: four US drug approvals, three UK developments and two global R&D deals. The FDA approved Atebrioz, the third treatment for fibrodysplasia ossificans progressiva, and AbbVie’s Parkinson’s drug Juvmo. The MHRA approved...

Multi-Cancer Early Detection Test Divides FDA Advisers

A United States advisory panel has recommended approval of a multi-cancer early detection blood test. The Molecular and Clinical Genetics Panel of the Medical Devices Advisory Committee met on 23 September 2026. It reviewed GRAIL’s Galleri test. The assay reads...

Merck Wnt Agonist Meets Diabetic Macular Oedema Treatment Goal

Merck said on 24 September 2026 that remigromig met the primary endpoint of the pivotal Phase 2b/3 BRUNELLO study. Merck is known as MSD outside the United States and Canada. It said no new diabetic macular oedema treatment mechanism had matched anti-VEGF therapy in...

Online Prescribing Is Moving Faster Than Regulation

Online prescribing has moved from being a relatively niche part of healthcare to an increasingly established route through which patients access treatment. That change brings clear benefits. Patients can seek treatment discreetly, access clinicians without travelling,...

Clinical Trials Roundup | 25 September 2026

The clinical trial results 25 September 2026 span Sjögren’s, urticaria, IgA nephropathy, obesity, cutaneous lupus and Alzheimer’s psychosis. Amgen’s dazodalibep met its primary endpoint in systemic Sjögren’s disease. Celldex’s barzolvolimab met its primary and all key...

Rethinking the Office: The Need for Healthier Buildings

For property owners, management companies, and business leaders, few sights are more unwelcome than an empty office building. Indoor air quality may be part of the answer to filling it. In the post-pandemic era, the home office has replaced the traditional workplace...

When Life Sciences Compliance Problems Are Really Operations Problems

When a life sciences organization struggles during a regulatory inspection or quality audit, the first reaction is fairly predictable: people point to evolving regulatory expectations, expanding documentation requirements, or the complexity of maintaining compliance...

Obesity Drug Access in the UK: NHS and Private Routes in 2026

Obesity drug access in the UK now runs along two tracks that rarely meet. One is a publicly funded NHS rollout of tirzepatide (Mounjaro), phased over as long as 12 years. The other is a private market that has grown far faster. A UCL survey estimates that about 1.6...

Transfusion Medicine in 2026: from Hemovigilance to Bedside Precision

Transfusion medicine plays a crucial role in modern healthcare by ensuring the availability of safe and compatible blood products for patients in need. Recognized globally as an essential medicine, blood remains the cornerstone of the healthcare workflow.  Every few...

Want to Be Part of the Next Chapter in Life Sciences Media?

 

LifeScienceDaily.news is building a new kind of platform where innovators, researchers, and industry leaders tell their own stories and shape the narrative of what’s next in life sciences. Share your story and lead the conversation.

 

 

Don’t wait for the media to pick up your story. Be the media.

See More Articles

Want to Be Part of the Next Chapter in Life Sciences Media?

 

LifeScienceDaily.news is building a new kind of platform where innovators, researchers, and industry leaders tell their own stories and shape the narrative of what’s next in life sciences. Share your story and lead the conversation.

 

 

Don’t wait for the media to pick up your story. Be the media.